133 related articles for article (PubMed ID: 34504954)
1. Sodium-dependent phosphate transporter NaPi2b as a potential predictive marker for targeted therapy of ovarian cancer.
Nurgalieva AK; Popov VE; Skripova VS; Bulatova LF; Savenkova DV; Vlasenkova RA; Safina SZ; Shakirova EZ; Filonenko VV; Bogdanov MV; Kiyamova RG
Biochem Biophys Rep; 2021 Dec; 28():101104. PubMed ID: 34504954
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal antibody MX35 detects the membrane transporter NaPi2b (SLC34A2) in human carcinomas.
Yin BW; Kiyamova R; Chua R; Caballero OL; Gout I; Gryshkova V; Bhaskaran N; Souchelnytskyi S; Hellman U; Filonenko V; Jungbluth AA; Odunsi K; Lloyd KO; Old LJ; Ritter G
Cancer Immun; 2008 Feb; 8():3. PubMed ID: 18251464
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical evaluation of epithelial ovarian carcinomas identifies three different expression patterns of the MX35 antigen, NaPi2b.
Levan K; Mehryar M; Mateoiu C; Albertsson P; Bäck T; Sundfeldt K
BMC Cancer; 2017 May; 17(1):303. PubMed ID: 28464843
[TBL] [Abstract][Full Text] [Related]
4. Toward a Topology-Based Therapeutic Design of Membrane Proteins: Validation of NaPi2b Topology in Live Ovarian Cancer Cells.
Bulatova L; Savenkova D; Nurgalieva A; Reshetnikova D; Timonina A; Skripova V; Bogdanov M; Kiyamova R
Front Mol Biosci; 2022; 9():895911. PubMed ID: 35911971
[TBL] [Abstract][Full Text] [Related]
5. The study of phosphate transporter NAPI2B expression in different histological types of epithelial ovarian cancer.
Gryshkova V; Goncharuk I; Gurtovyy V; Khozhayenko Y; Nespryadko S; Vorobjova L; Usenko V; Gout I; Filonenko V; Kiyamova R
Exp Oncol; 2009 Mar; 31(1):37-42. PubMed ID: 19300415
[TBL] [Abstract][Full Text] [Related]
6. Generation of monoclonal antibodies against tumor-associated antigen MX35/sodium-dependent phosphate transporter NaPi2b.
Gryshkova V; Lituiev D; Savinska L; Ovcharenko G; Gout I; Filonenko V; Kiyamova R
Hybridoma (Larchmt); 2011 Feb; 30(1):37-42. PubMed ID: 21466284
[TBL] [Abstract][Full Text] [Related]
7. The Dolaflexin-based Antibody-Drug Conjugate XMT-1536 Targets the Solid Tumor Lineage Antigen SLC34A2/NaPi2b.
Bodyak ND; Mosher R; Yurkovetskiy AV; Yin M; Bu C; Conlon PR; Demady DR; DeVit MJ; Gumerov DR; Gurijala VR; Lee W; McGillicuddy D; Park PU; Poling LL; Protopova M; Qin L; Stevenson CA; Ter-Ovanesyan E; Uttard A; Xiao D; Xu J; Xu L; Bergstrom DA; Lowinger TB
Mol Cancer Ther; 2021 May; 20(5):896-905. PubMed ID: 33722858
[TBL] [Abstract][Full Text] [Related]
8. In silico analysis and immunohistochemical characterization of NaPi2b protein expression in ovarian carcinoma with monoclonal antibody Mx35.
Soares IC; Simões K; de Souza JE; Okamoto OK; Wakamatsu A; Tuma M; Ritter G; Alves VA
Appl Immunohistochem Mol Morphol; 2012 Mar; 20(2):165-72. PubMed ID: 22553815
[TBL] [Abstract][Full Text] [Related]
9. Preclinical Development of an Anti-NaPi2b (SLC34A2) Antibody-Drug Conjugate as a Therapeutic for Non-Small Cell Lung and Ovarian Cancers.
Lin K; Rubinfeld B; Zhang C; Firestein R; Harstad E; Roth L; Tsai SP; Schutten M; Xu K; Hristopoulos M; Polakis P
Clin Cancer Res; 2015 Nov; 21(22):5139-50. PubMed ID: 26156394
[TBL] [Abstract][Full Text] [Related]
10. Targeting NaPi2b in ovarian cancer.
Banerjee S; Drapkin R; Richardson DL; Birrer M
Cancer Treat Rev; 2023 Jan; 112():102489. PubMed ID: 36446254
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical analysis of NaPi2b protein (MX35 antigen) expression and subcellular localization in human normal and cancer tissues.
Kiyamova R; Shyian M; Lyzogubov VV; Usenko VS; Gout T; Filonenko V
Exp Oncol; 2011 Sep; 33(3):157-61. PubMed ID: 21956469
[TBL] [Abstract][Full Text] [Related]
12. Characterization of
Vlasenkova R; Nurgalieva A; Akberova N; Bogdanov M; Kiyamova R
Biomolecules; 2021 Dec; 11(12):. PubMed ID: 34944522
[TBL] [Abstract][Full Text] [Related]
13. Quantitative analysis of SLC34A2 expression in different types of ovarian tumors.
Shyian M; Gryshkova V; Kostianets O; Gorshkov V; Gogolev Y; Goncharuk I; Nespryadko S; Vorobjova L; Filonenko V; Kiyamova R
Exp Oncol; 2011 Jun; 33(2):94-8. PubMed ID: 21716206
[TBL] [Abstract][Full Text] [Related]
14. Characterization of novel human ovarian cancer-specific transcripts (HOSTs) identified by serial analysis of gene expression.
Rangel LB; Sherman-Baust CA; Wernyj RP; Schwartz DR; Cho KR; Morin PJ
Oncogene; 2003 Oct; 22(46):7225-32. PubMed ID: 14562052
[TBL] [Abstract][Full Text] [Related]
15. High expression of SLC34A2 is a favorable prognostic marker in lung adenocarcinoma patients.
Zhang Z; Ye S; Zhang M; Wu J; Yan H; Li X; He J
Tumour Biol; 2017 Jul; 39(7):1010428317720212. PubMed ID: 28720066
[TBL] [Abstract][Full Text] [Related]
16. Development of monoclonal antibodies specific for the human sodium-dependent phosphate co-transporter NaPi2b.
Kiyamova R; Gryshkova V; Ovcharenko G; Lituyev D; Malyuchik S; Usenko V; Khozhayenko Y; Gurtovyy V; Yin B; Ritter G; Old L; Filonenko V; Gout I
Hybridoma (Larchmt); 2008 Aug; 27(4):277-84. PubMed ID: 18724815
[TBL] [Abstract][Full Text] [Related]
17. Solute carrier family 34 member 2 overexpression contributes to tumor growth and poor patient survival in colorectal cancer.
Liu L; Yang Y; Zhou X; Yan X; Wu Z
Biomed Pharmacother; 2018 Mar; 99():645-654. PubMed ID: 29653487
[TBL] [Abstract][Full Text] [Related]
18. Upregulation of centrosomal protein 55 is associated with unfavorable prognosis and tumor invasion in epithelial ovarian carcinoma.
Zhang W; Niu C; He W; Hou T; Sun X; Xu L; Zhang Y
Tumour Biol; 2016 May; 37(5):6239-54. PubMed ID: 26615423
[TBL] [Abstract][Full Text] [Related]
19. SLC34A2 as a novel marker for diagnosis and targeted therapy of breast cancer.
Chen DR; Chien SY; Kuo SJ; Teng YH; Tsai HT; Kuo JH; Chung JG
Anticancer Res; 2010 Oct; 30(10):4135-40. PubMed ID: 21036732
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
